Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic Significance of Cellular Cannibalism in Colorectal Tumors.

International journal of surgical pathology·2026
Same author

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).

International journal of cancer·2026
Same author

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Cancers·2026
Same author

Outcomes and Complications After LUMiC<sup>®</sup> Endoprosthetic Reconstruction of Periacetabular Defects-A Retrospective Cohort Analysis.

Life (Basel, Switzerland)·2026
Same author

Feasibility and Concordance of a Large Language Model (ChatGPT-5) as a Clinical Decision Support Tool in Gynecologic Oncology Tumor Boards: A Blinded, Multi-Observer Study.

Journal of clinical medicine·2026
Same author

Efficacy and Tolerability of Pazopanib in Elderly Patients with Advanced Soft Tissue Sarcoma: A Multicentre Real-World Study from Turkey.

Journal of clinical medicine·2026

相关实验视频

Updated: Sep 10, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

845

在转移性脉状腺癌中,前线的FOLFIRINOX与基于酸和基于凝的化疗方法的比较:土耳其瘤学小组 (TOG) 的多中心研究

Ali Kalem1, Tulay Kus1, Savas Gokcek2

  • 1Department of Medical Oncology, School of Medicine, Gaziantep University, Gaziantep 27310, Turkey.

Journal of clinical medicine
|August 28, 2025
PubMed
概括
此摘要是机器生成的。

尽管有增加的毒性,前线的FOLFIRINOX化疗对于晚期的囊腺癌显示出改善肠道亚型的生存趋势. 结果与胰腺胆亚型的其他疗法相似.

关键词:
其他药物:脉瘤基于gemcitabine的药物肠道亚型发生转移胰腺胆亚型

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

370

相关实验视频

Last Updated: Sep 10, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

845
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

370

科学领域:

  • 癌症学
  • 胃肠病学
  • 临床治疗方法

背景情况:

  • 囊腺癌是一种罕见的癌症,对转移性疾病的有效第一线治疗数据有限.
  • 与其他化疗方案相比,研究FOLFIRINOX作为一线治疗的疗效对于晚期病例至关重要.

研究的目的:

  • 为了比较第一线FOLFIRINOX化疗与其他治疗在晚期囊腺癌患者的结果.
  • 根据组织学亚型,评估不同化疗方案对无进展生存率和整体生存率的影响.

主要方法:

  • 对123名先进的囊腺癌患者进行了回顾性研究,这些患者接受了前线的FOLFIRINOX,基于 (FU) 的化学疗法或基于gemcitabine的化学疗法.
  • 使用卡普兰-梅尔方法分析无病变生存时间 (mPFS) 和总生存时间 (mOS) 的中位数.
  • 基于治疗方案和临床病理特征的结果比较,包括组织学亚型.

主要成果:

  • 在所有组织学亚型中,不同化疗剂之间没有观察到总生存率 (OS) 的显著差异.
  • 基于FOLFIRINOX和FU的治疗方法在肠道亚型中显示出更高的疗效,而基于gemcitabine的治疗方法效果较差.
  • 与基于FOLFIRINOX和基于gemcitabine的疗法相比,基于FU的疗法导致胰腺胆亚型的治疗结果更短.
  • 在接受FOLFIRINOX的患者中,发现了较高的3级或4级血液毒性.

结论:

  • 尽管有增加的毒性,FOLFIRINOX在晚期囊腺癌的肠子类型中显示出改善的生存系统趋势.
  • 在胰腺胆亚型中,FOLFIRINOX的结果与其他疗法相似.
  • 晚期囊腺癌的组织学亚型可能会影响化疗选择.